Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
J02AC01 MYXEN G Fluconazole - 50mg/5ml 50mg/5ml Granules for suspension 793,507 L.L
N02BE51 MAXIFEN G Paracetamol - 325mg, Ibuprofen - 400mg Tablet, scored 225,254 L.L
R03DC03 MONTELUKAST ARROW LAB G Montelukast (sodium) - 5mg 5mg Tablet, chewable 851,996 L.L
R03DC03 MONTELUKAST-SANDOZ G Montelukast (sodium) - 5mg 5mg Tablet, chewable 1,139,034 L.L
G01AF02 MICOTER GYNO OVULE G Clotrimazole - 500mg 500mg Pessary 447,948 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 1000mg 1000mg Tablet, film coated, scored 237,860 L.L
J02AC01 MYXEN G Fluconazole - 50mg 50mg Tablet 755,112 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 1000mg 1000mg Tablet, film coated, scored 689,391 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 1000mg 1000mg Tablet, film coated, scored 237,860 L.L
G01AF04 MYCODERM-V G Miconazole nitrate - 2% 2% Cream 361,494 L.L
A10BA02 MINOR G Metformin HCl - 1g 1g Tablet 266,209 L.L
J01DD08 MAGNACEF G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 349,399 L.L
M03BA03 METOFLEX G Methocarbamol - 750mg 750mg Tablet 2,941,671 L.L
R03DC03 MONTELUKAST ARROW LAB G Montelukast (sodium) - 10mg 10mg Tablet, film coated 978,317 L.L
R03DC03 MONTELUKAST-SANDOZ G Montelukast (sodium) - 10mg 10mg Tablet, film coated 1,093,012 L.L
M03BA53 METHOFEN PLATINUM G Ibuprofen - 200mg, Methocarbamol - 500mg Tablet 668,082 L.L
R03DC03 MOTRINEX G Montelukast - 10mg 10mg Tablet, film coated 802,274 L.L
S01EE01 MONOPROST G Latanoprost - 50mcg/ml 50mcg/ml Drops solution 1,187,957 L.L
A12CC MAVIT G Magnesium - 100mg, Pyridoxine HCl - 10mg Tablet 654,003 L.L
G01AF20 MICOGYL G Metronidazole - 500mg, Miconazole nitrate - 100mg Suppository 362,198 L.L
J01DD08 MAGNACEF G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 700,142 L.L
D01AC02 MICONAZ G Miconazole nitrate - 20mg/g 20mg/g Gel 427,470 L.L
J01DD08 MUREX G Cefixime (trihydrate) - 100mg/5ml 100mg/5ml Powder for suspension 528,130 L.L
J02AC01 MYXEN G Fluconazole - 150mg 150mg Tablet 255,970 L.L
A10BA02 METFORKEY G Metformin HCl - 1.000mg 1.000mg Tablet, extended release 374,932 L.L
M03BC51 MUSCEROL 2 G Paracetamol - 450mg, Orphenadrine (citrate) - 35mg Tablet, scored 177,899 L.L
M03BC51 MUSCEROL EXTRA G Caffeine - 15mg, Paracetamol - 450mg, Orphenadrine citrate - 35mg Tablet, scored 267,489 L.L
R03DC03 MONTELUKAST ARROW LAB G Montelukast (sodium) - 4mg 4mg Tablet, chewable 851,996 L.L
M03BC51 MUSCEROL 3 G Paracetamol - 450mg, Orphenadrine citrate - 35mg, Ibuprofen - 200mg Tablet, film coated 593,850 L.L
R03DC03 MONTELUKAST-SANDOZ G Montelukast (sodium) - 4mg 4mg Tablet, chewable 1,139,034 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025